Host bacterium specific nanoparticle

Patent metadata

Field	Value
Publication number	US-11939592-B2
Application number	US-201917275401-A
Country	US
Kind code	B2
Filing date	Dec 5, 2019
Priority date	Dec 27, 2018
Publication date	Mar 26, 2024
Grant date	Mar 26, 2024

Abstract

An object of the present invention is to provide a recombinant phage having high safety and excellent practicality and usefulness. Provided are a recombinant bacteriophage which is deprived of its proliferative capacity and can infect only once due to the fact that a bacteriophage genome in which a part of a virion constituent gene is deleted is stored in a head, and a method for preparing the same. In addition, provided are a recombinant bacteriophage which is deprived of its proliferative capacity and can infect only once due to the fact that a plasmid having a packaging site and encoding a target gene is stored in a head, and a method for preparing the same.

First claim

The invention claimed is:

1. A nanoparticle, consisting of a recombinant bacteriophage that includes a head and a tail, and has an ability to infect but no ability to reinfect a host bacterium, the head having stored therein a bacteriophage genome in which a part of a virion constituent gene is deleted, and
wherein the part of the virion constituent gene which is deleted is a tail gene.

2. The host bacterium-specific nanoparticle according to claim 1 , wherein the bacteriophage genome is a genome of T7 phage.

3. An antibacterial agent comprising the nanoparticle according to claim 1 as an active ingredient.

4. A composition comprising the antibacterial agent according to claim 3 .

5. The composition according to claim 4 , which is a pharmaceutical, disinfectant, cleaning agent, or oral composition against bacterial infections.

6. A nanoparticle, consisting of a recombinant bacteriophage that comprises a head and a tail, and has an ability to infect but no ability to re-infect a host bacterium,
the head having stored therein a plasmid comprising a bacteriophage genome in which a part of a virion constituent gene is deleted having a packaging site and encoding the target gene, wherein the part of the virion constituent gene which is deleted is a tail gene.

7. The nanoparticle according to claim 6 , wherein the bacteriophage genome is a genome of T7 phage.

8. The nanoparticle according to claim 6 , wherein the target gene is one or more genes selected from the group consisting of a marker gene, a reporter gene, an enzyme gene, a gene for genome editing, a gene encoding an antibacterial peptide, an antibacterial gene, and a group of genes constituting a synthetic gene circuit.

9. A composition for transduction, comprising the nanoparticle according to claim 6 as an active ingredient.

10. A recombinant bacteriophage comprising a head and a tail, and having an ability to infect but no ability to re-infect a host bacterium,
the head having stored therein a bacteriophage genome in which a part of a virion constituent gene is deleted.

11. The recombinant bacteriophage according to claim 10 , wherein the recombinant bacteriophage is a virulent phage.

12. A pharmaceutical composition comprising the recombinant bacteriophage according to claim 10 and an excipient.

Assignees

• National Univ Corporation Tokai National Higher Education And Research System

Inventors

• MITSUNAKA Shoichi
• Ando Hiroki

Classifications

• C12N7/045

  Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered · CPC title

• C12N1/20

  Bacteria; Culture media therefor · CPC title

• A61K35/74

  Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title

• C12N15/86 Primary

  Viral vectors · CPC title

• A61P1/02 Primary

  Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis · CPC title